Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 in frontotemporal dementia with GRN or C9orf72 mutations
NCT03987295Phase 2Completed
- Sponsor
- Alector
- Start
- Sep 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of AL001 in frontotemporal dementia (FTD), sponsored by Alector. Started Sep 2019; status: completed.
02
Drugs
AL001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT03987295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987295.